Clinical Trial

A Trial of SHR-A2102 With or Without Antitumor Therapy in Advanced Solid Tumors

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-A2102 for injection with or without Antitumor Therapy in Advanced Solid Tumors. To explore the reasonable dosage of SHR-A2102 for Advanced Solid Tumors.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-05-11.
Status change: Not Yet Recruiting → Recruiting 2024-12-29
Trial Details
NCT Number NCT06417554
Lead Sponsor Shanghai Hengrui Pharmaceutical Co., Ltd.
Conditions Advanced Solid Tumors
Enrollment 80 participants
Start Date 2024-05-13
Primary Completion 2027-07 (estimated)
Study Completion 2027-07 (estimated)
Updated on ClinicalTrials.gov 2024-12-31